## Jeri W Nieves

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1721755/publications.pdf Version: 2024-02-01



IEDI W NIEVES

#	Article	IF	CITATIONS
1	Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet, The, 1997, 350, 550-555.	6.3	713
2	Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study*. Journal of Bone and Mineral Research, 2001, 16, 1846-1853.	3.1	580
3	A Novel Tetracycline Labeling Schedule for Longitudinal Evaluation of the Short-Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide. Journal of Bone and Mineral Research, 2005, 21, 366-373.	3.1	248
4	Males Have Larger Skeletal Size and Bone Mass Than Females, Despite Comparable Body Size. Journal of Bone and Mineral Research, 2004, 20, 529-535.	3.1	245
5	Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate. New England Journal of Medicine, 2005, 353, 566-575.	13.9	245
6	Osteoporosis: the role of micronutrients. American Journal of Clinical Nutrition, 2005, 81, 1232S-1239S.	2.2	243
7	Effects Of a One-Month Treatment With PTH(1-34) on Bone Formation on Cancellous, Endocortical, and Periosteal Surfaces of the Human Ilium. Journal of Bone and Mineral Research, 2007, 22, 495-502.	3.1	219
8	Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis. Journal of Bone and Mineral Research, 2017, 32, 198-202.	3.1	181
9	Resistance to Bone Resorbing Effects of PTH in Black Women. Journal of Bone and Mineral Research, 1997, 12, 958-966.	3.1	173
10	Nutrition and Sarcopenia—What Do We Know?. Nutrients, 2020, 12, 1755.	1.7	152
11	Anabolic Action of Parathyroid Hormone Is Skeletal Site Specific at the Tissue and Cellular Levels in Mice. Journal of Bone and Mineral Research, 2002, 17, 808-816.	3.1	129
12	Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. Journal of Bone and Mineral Research, 1995, 10, 1393-1399.	3.1	127
13	Nutritional Factors That Influence Change in Bone Density and Stress Fracture Risk Among Young Female Cross ountry Runners. PM and R, 2010, 2, 740-750.	0.9	127
14	Alendronate Does Not Block the Anabolic Effect of PTH in Postmenopausal Osteoporotic Women. Journal of Bone and Mineral Research, 1998, 13, 1051-1055.	3.1	108
15	Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Annals of Internal Medicine, 2016, 165, 867.	2.0	84
16	Histomorphometric Assessment of Bone Mass, Structure, and Remodeling: A Comparison Between Healthy Black and White Premenopausal Women. Journal of Bone and Mineral Research, 1997, 12, 948-957.	3.1	78
17	Atypical Subtrochanteric and Femoral Shaft Fractures and Possible Association with Bisphosphonates. Current Osteoporosis Reports, 2010, 8, 34-39.	1.5	77
18	Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 1425.	4.5	74

JERI W NIEVES

#	Article	IF	CITATIONS
19	When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS ONE, 2013, 8, e83306.	1.1	63
20	Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate. Journal of Bone and Mineral Research, 2016, 31, 1518-1526.	3.1	35
21	Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women. Gastroenterology, 2019, 156, 926-934.e6.	0.6	35
22	Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2769-2776.	1.8	33
23	Effect of Teriparatide on Bone Formation in the Human Femoral Neck. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1498-1505.	1.8	33
24	Modelingâ€Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab. Journal of Bone and Mineral Research, 2020, 35, 1282-1288.	3.1	30
25	Calcium, vitamin D, and nutrition in elderly adults. Clinics in Geriatric Medicine, 2003, 19, 321-335.	1.0	29
26	Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. Journal of Bone and Mineral Research, 2016, 31, 1466-1472.	3.1	29
27	Sex-Differences in Skeletal Growth and Aging. Current Osteoporosis Reports, 2017, 15, 70-75.	1.5	27
28	Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial. Journal of Bone and Mineral Research, 2018, 33, 763-772.	3.1	27
29	Improved fracture prediction using different fracture risk assessment tool adjustments in HIV-infected women. Aids, 2018, 32, 1699-1706.	1.0	26
30	Comparative assessment of bone mineral density of the forearm using single photon and dual X-ray absorptiometry. Calcified Tissue International, 1992, 51, 352-355.	1.5	25
31	Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis. Nutrients, 2021, 13, 2273.	1.7	25
32	Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease. Blood Advances, 2018, 2, 969-978.	2.5	24
33	Maximizing bone health—magnesium, BMD and fractures. Nature Reviews Endocrinology, 2014, 10, 255-256.	4.3	22
34	Results of a fracture liaison service on hip fracture patients in an open healthcare system. Aging Clinical and Experimental Research, 2017, 29, 331-334.	1.4	22
35	Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective?. Osteoporosis International, 2020, 31, 2321-2335.	1.3	16
36	Eating disorders, menstrual dysfunction, weight change and DMPA use predict bone density change in college-aged women. Bone, 2016, 84, 113-119.	1.4	15

JERI W NIEVES

#	Article	IF	CITATIONS
37	Administration of teriparatide for four years cyclically compared to two years daily in treatment NaÃ <sup>-</sup> ve and alendronate treated women. Bone, 2019, 120, 246-253.	1.4	15
38	Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial. Journal of Bone and Mineral Research, 2020, 35, 219-225.	3.1	15
39	Parathyroid Responsivity in Postmenopausal Women with Osteoporosis During Treatment with Parathyroid Hormone1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 788-790.	1.8	14
40	ldentification of prevalent vertebral fractures using Vertebral Fracture Assessment (VFA) in asymptomatic postmenopausal women: A systematic review and meta-analysis. Bone, 2020, 136, 115358.	1.4	14
41	A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material. Contemporary Clinical Trials Communications, 2016, 4, 14-24.	0.5	13
42	Perspective: US Documentation and Regulation of Human Nutrition Randomized Controlled Trials. Advances in Nutrition, 2021, 12, 21-45.	2.9	13
43	Evaluation of continuous summary physical performance scores (CSPPS) in an elderly cohort. Aging Clinical and Experimental Research, 2005, 17, 193-200.	1.4	11
44	Case-control study in ALS using the National ALS Registry: lead and agricultural chemicals are potential risk factors. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 190-202.	1.1	11
45	The clinically meaningful change in physical performance scores in an elderly cohort. Aging Clinical and Experimental Research, 2007, 19, 484-491.	1.4	10
46	Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial. Osteoporosis International, 2022, 33, 239-250.	1.3	10
47	Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: Effects of estrogen therapy. Journal of Bone and Mineral Research, 1995, 10, 594-600.	3.1	8
48	Nutritional therapies (including fosteum). Current Osteoporosis Reports, 2009, 7, 5-11.	1.5	7
49	Calcium and fracture risk. American Journal of Clinical Nutrition, 2007, 86, 1579-1580.	2.2	7
50	Abnormal microarchitecture and stiffness in postmenopausal women with isolated osteoporosis at the 1/3 radius. Bone, 2020, 132, 115211.	1.4	6
51	Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck. Bone, 2022, 157, 116342.	1.4	6
52	No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients. Bone Reports, 2020, 12, 100253.	0.2	5
53	Loading modality and age influence teriparatide-induced bone formation in the human femoral neck. Bone, 2020, 136, 115373.	1.4	5
54	Determining the Effects of a 4-Week Structured Strength and Flexibility Exercise Program on Functional Status of Subjects with Osteoporosis. HSS Journal, 2019, 15, 241-246.	0.7	3

JERI W NIEVES

#	Article	IF	CITATIONS
55	Regional Differences in Incident Prefrailty and Frailty. Journal of Women's Health, 2017, 26, 992-998.	1.5	2
56	Reply. Gastroenterology, 2019, 157, 586.	0.6	1
57	THU0472â€Factors associated with readiness for adopting osteoporosis treatment change. , 2018, , .		0
58	THU0490â€Temporal increases in side effect concerns of osteoporosis medications among women with previous fractures. , 2018, , .		0